Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07467993) titled 'Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia' on March 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Schizophrenia
Intervention:
Drug: GXV813
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 20, 2026
Target Sample Size: 142
To know more, visit https://clinicaltrials.gov/study/...